Revolutionary Heart Failure Therapy Company Also Adds New Executive and Well-Known Board Member to Enhance Expertise
BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), today announced that it has acquired MateraCor, Inc., a company focused on preventing progression of, and reversing, heart failure through the use of injectable alginate-based hydrogel.
“This is an exciting time for BioVentrix as we build a platform of synergistic therapies to treat a dilated left ventricle, the root cause of ischemic and idiopathic heart failure,” said Jim Dillon, President and CEO, BioVentrix. “The acquisition of MateraCor, Inc., and their lead product, Trans-Catheter Myocardial Restoration (TCMR), reinforces our position to treat left ventricular heart failure by offering a variety of solutions that will directly impact ventricular remodeling through less invasive LV restoration technologies.”
The company also announced it has named Steve Chartier as Chief Operating Officer, and that Professor Andrew Coats will join the Company’s Board of Directors, further expanding its expertise in developing and commercializing heart failure technology. The addition of Steve Chartier to the executive team will enhance the company’s expertise in global regulatory strategy, operations and clinical product development. Professor Andrew Coats, a world-renowned heart failure cardiologist, is joining the board to help guide the company to even greater growth within the heart failure market.